NewLimit

NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

Health and bioEducation

NewLimit raised $435M in a Series B+ round announced June 2, 2026, according to x.com. Across 2 sourced rounds it has raised $565M in total. Investors in that round: Founders Fund.

Raise history

1. September 29, 2026
   First seen by Recent Funding
   via startups.gallery
2. June 2, 2026
   Series B+ · $435M
   FFounders Fund (lead)
   Source: x.com (startups.gallery listing)
3. May 6, 2025
   Series B+ · $130M
   KKleiner Perkins (lead)
   Source: blog.newlimit.com (startups.gallery listing)

Investors

• FFounders Fund
• GGreenoaks
• HHuman Ventures
• KKhosla Ventures
• KKleiner Perkins
• NNFDG Ventures
• TThrive Capital
• VValor Equity Partners

Related other companies

• QQuartermaster$140M · Sep 28, 2026
• SSnorkel AI$350M · Sep 23, 2026
• EEnveda$311M · Sep 23, 2026
• HHeidi Health$100M · Sep 22, 2026
• FFirecrawl$75M · Sep 22, 2026
• CCorridor$25M · Sep 21, 2026
• JJack & Jill$40M · Sep 19, 2026
• MMithr Inc.$20M · Sep 19, 2026

Every amount links to the page it came from. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/newlimit.